Adaptimmune Therapeutics, a developer of T-cell therapies to treat cancer, and Cryoport, Inc., a temperature-controlled logistics solutions company dedicated to the life sciences industry, have entered a three-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies. Adaptimmune aims to optimize manufacturing and supply operations and reduce “vein-to-vein” time for patients in clinical trials and ahead of commercialization. This agreement with Cryoport will ...